First Time Loading...

BiVictriX Therapeutics PLC
LSE:BVX

Watchlist Manager
BiVictriX Therapeutics PLC Logo
BiVictriX Therapeutics PLC
LSE:BVX
Watchlist
Price: 11.5 GBX -4.17% Market Closed
Updated: May 8, 2024

Profitability Summary

BiVictriX Therapeutics PLC's profitability score is 27/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score
27/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
BiVictriX Therapeutics PLC

Revenue
0 GBP
Operating Expenses
-2.8m GBP
Operating Income
-2.8m GBP
Other Expenses
487k GBP
Net Income
-2.3m GBP

Margins Comparison
BiVictriX Therapeutics PLC Competitors

Country Company Market Cap Operating
Margin
Net
Margin
UK
BiVictriX Therapeutics PLC
LSE:BVX
9.5m GBP N/A N/A
US
Abbvie Inc
NYSE:ABBV
287.1B USD
30%
9%
US
Amgen Inc
NASDAQ:AMGN
161.1B USD
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.7B USD
39%
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.9B USD
30%
29%
AU
CSL Ltd
ASX:CSL
135.1B AUD
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
81.6B USD
32%
2%
US
Moderna Inc
NASDAQ:MRNA
46.4B USD
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
31.9B USD
22%
12%
KR
Celltrion Inc
KRX:068270
40.3T KRW
30%
25%
Country UK
Market Cap 9.5m GBP
Operating Margin N/A
Net Margin N/A
Country US
Market Cap 287.1B USD
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 161.1B USD
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 105.7B USD
Operating Margin
39%
Net Margin
37%
Country US
Market Cap 106.9B USD
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 135.1B AUD
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 81.6B USD
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 46.4B USD
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 31.9B USD
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 40.3T KRW
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
BiVictriX Therapeutics PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
BiVictriX Therapeutics PLC
LSE:BVX
9.5m GBP
-59%
-51%
-70%
-223%
US
Abbvie Inc
NYSE:ABBV
287.1B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
161.1B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.7B USD
23%
18%
22%
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.9B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
135.1B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
81.6B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
46.4B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
31.9B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
40.3T KRW
5%
4%
6%
4%
Country UK
Market Cap 9.5m GBP
ROE
-59%
ROA
-51%
ROCE
-70%
ROIC
-223%
Country US
Market Cap 287.1B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 161.1B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 105.7B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country US
Market Cap 106.9B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 135.1B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 81.6B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 46.4B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 31.9B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 40.3T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More